Onkonephrologie am Beispiel des Plasmazellmyeloms – Was Nephrologen und Hämatoonkologen voneinander lernen können

Abstract

Plasma cell diseases, in particular multiple myeloma, represent an interdisciplinary challenge for oncologists and nephrologists. Patients often present initially with kidney problems to a nephrologist, requiring timely diagnosis and referral to an oncologist for treatment. On the other hand, a relevant part of patients will experience a – mostly temporary – decline in kidney function during the treatment course, which may require nephrological care. In any case, renal insufficiency can affect the therapeutic options. This article provides a short overview about common nephrological factors and complications which impact on the manifestation and course of treatment in patients with plasma cell diseases.

Plasmazellerkrankungen, v. a. das Multiple Myelom, stellen eine interdisziplinäre Herausforderung für Nephrologen und Hämatoonkologen dar. Beide Fachrichtungen sind involviert, wenn sich beim Initialbefund einer Nierenfunktionsverschlechterung kausal ein Plasmazellmyelom herausstellt oder wenn eine Niereninsuffizienz im Verlauf der Therapie auftritt. Welche Aspekte dann in Bezug auf Medikation und Behandlungsverlauf relevant sind, zeigt dieser Beitrag.

Schlüsselwörter

Plasmazellmyelom - Paraprotein - freie Leichtketten - Niereninsuffizienz, Dialyse

Key words

plasma cell myeloma - paraprotein - free light chain - renal insufficiency - dialysis

Publication History

Article published online:
17 June 2020

• Literatur

• 1 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of Multiple myeloma. Lancet Oncol 2014; 15: e538-e548
• 2 Leung N, Bridoux F, Batuman V. et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019; 15: 45-59
• 3 Yadav P, Cockwell P, Cook M. et al. Serum free light chain levels and renal function at diagnosis in patients with Multiple myeloma. BMC Nephrol 2018; 19: 178
• 4 Andronesi AG, Tanase AD, Sorohan BM. et al. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for Multiple myeloma. Cancer Med 2019; 8: 3278-3285
• 5 Nasr SH, Valeri AM, Sethi S. et al. Clinicopathologic correlations in Multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012; 59: 786-794
• 6 Levi M, Ellis MA, Berl T. Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 1983; 71: 1624-1632
• 7 Khera A, Panitsas F, Djebbari F. et al. Long term outcomes in monoclonal gammopathy of renal significance. Br J Haematol 2019; 186: 706-716
• 8 Mohan M, Buros A, Mathur P. et al. Clinical characteristics and prognostic factors in Multiple myeloma patients with light chain deposition disease. Am J Hematol 2017; 92: 739-745
• 9 Paueksakon P, Revelo MP, Horn RG. et al. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003; 42: 87-95
• 10 Fish R, Pinney J, Jain P. et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010; 5: 1977-1978
• 11 Dimopoulos MA, Sonneveld P, Leung N. et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016; 34: 1544-1557
• 12 Clark WF, Stewart AK, Rock GA. et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777-784
• 13 Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364: 2365-2366
• 14 Bridoux F, Carron PL, Pegourie B. et al. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. JAMA 2017; 318: 2099-2110
• 15 Hutchison CA, Cockwell P, Moroz V. et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol 2019; 6: e217-e228
• 16 Lum EL, Bunnapradist S. Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. Curr Opin Nephrol Hypertens 2019; 28: 573-580
• 17 Wanchoo R, Abudayyeh A, Doshi M. et al. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol 2017; 12: 176-189
• 18 Batalini F, Econimo L, Quillen K. et al. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant 2018; 24: 127-132
• 19 Bird JM, Fuge R, Sirohi B. et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385-390
• 20 St Bernard R, Chodirker L, Masih-Khan E. et al. Efficacy, toxicity and mortality of autologous SCT in Multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 2015; 50: 95-99
• 21 Hartmann B, Czock D, Keller F. Arzneimitteltherapie bei Patienten mit chronischem Nierenversagen (Drug Therapy in Patients With Chronic Renal Failure). Dtsch Arztebl Int 2010; 107: 647-656